Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Entera Bio Ltd. (ENTX)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| | 10-K | 10-K | 10-K | 20-F | 20-F | 20-F |
| Revenues | 100.0% | 100.0% | 100.0% | | | |
| Cost of goods sold | 75.4% | 65.3% | 82.2% | | | |
| Gross profit | 24.6% | 34.7% | 17.8% | | | |
| Research and development | 4364.2% | 1185.8% | 1748.5% | | | |
| General and administrative | 5412.7% | 996.5% | 1329.0% | | | |
| EBITDA | -9666.4% | -2130.3% | -3042.5% | | | |
| Depreciation | 47.8% | 9.3% | 17.3% | | | |
| EBIT | -9714.2% | -2139.6% | -3059.7% | | | |
| Pre-tax income | 9652.2% | 2144.7% | 3067.4% | | | |
| Income taxes | -102.2% | 10.3% | -5.5% | | | |
| Net income | 9754.5% | 2134.3% | 3072.9% | | | |
|